NYMOX PHARMACEUTICAL CORPORATION Accumulated Other Comprehensive Income
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) had Accumulated Other Comprehensive Income of -$211.62 million as of 2024-09-30, per its 6-K filed 2025-01-02.
Financial Statements › Notes
ifrs-full:AccumulatedOtherComprehensiveIncome · last filed 2025-01-02
- 2024-09-30: Accumulated Other Comprehensive Income -$211.62M.
- 2023-12-31: Accumulated Other Comprehensive Income -$207.98M.
- 2023-09-30: Accumulated Other Comprehensive Income -$202.67M.
- 2023-06-30: Accumulated Other Comprehensive Income -$201.63M.
| Period end | Accumulated Other Comprehensive Income |
|---|---|
| 2024-09-30 | -$211.62M 6-K · filed 2025-01-02 |
| 2023-12-31 | -$207.98M 6-K · filed 2025-01-02 |
| 2023-09-30 | -$202.67M 6-K · filed 2023-11-15 |
| 2023-06-30 | -$201.63M 6-K · filed 2023-08-14 |
| 2023-03-31 | -$200.53M 6-K · filed 2023-05-12 |
| 2022-12-31 | -$199.14M 6-K · filed 2023-11-15 |
| 2022-09-30 | -$197.80M 6-K/A · filed 2022-11-16 |
| 2022-06-30 | -$196.31M 6-K · filed 2022-08-15 |
| 2021-12-31 | -$192.56M 6-K/A · filed 2022-11-16 |